Merck Manual

Please confirm that you are a health care professional




Brian J. Werth

, PharmD, University of Washington School of Pharmacy

Last full review/revision May 2020| Content last modified May 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version

Fosfomycin is a novel class of antibacterial drugs with a chemical structure unrelated to other known antibiotics. It is a bactericidal drug that disrupts cell wall synthesis by inhibiting phosphoenolpyruvate synthetase and thus interferes with the production of peptidoglycan.

In the US, it is available only as a powder formulation of fosfomycin tromethamine, which can be dissolved in liquid and taken orally. Outside the US, IV formulations are available.


Oral bioavailability of the fosfomycin tromethamine salt is low (about 40%), and, consequently, serum levels are low relative to the minimum inhibitory concentrations (MICs). For this reason, the drug is used to treat uncomplicated lower urinary tract infections, not pyelonephritis.

Fosfomycin does not bind to plasma proteins and distributes widely into tissues. Fosfomycin is excreted in urine mainly by glomerular filtration without biotransformation. After oral dosing, urinary levels exceed the MICs of susceptible pathogens for over 24 hours.

An IV formulation of fosfomycin is available in some countries and can be useful for more serious infections, including central nervous system infections, osteomyelitis, and pneumonia; when used to treat these infections, it is often used with other antibiotics such as beta-lactams.


Fosfomycin has a broad spectrum of activity against both gram-positive and gram-negative organisms, including many antibiotic-resistant organisms such as

Oral fosfomycin should be used only for uncomplicated (ie, lower) urinary tract infections caused by susceptible pathogens. However, because it has a broad spectrum of activity, IV fosfomycin is sometimes used to treat infections with multidrug-resistant organisms at other anatomic sites.


There are no significant contraindications to its use other than known hypersensitivity to fosfomycin or to any component of the formulation.

Use During Pregnancy and Breastfeeding

Fosfomycin crosses the placenta but is generally considered to be safe for treatment of cystitis in pregnant women.

How much fosfomycin enters breast milk is unknown, and caution is advised if treatment with fosfomycin is necessary for breastfeeding women.

Adverse Effects

Fosfomycin is generally well-tolerated and has a low rate of adverse effects, which include mainly gastrointestinal symptoms (eg, nausea, diarrhea).

Dosing Considerations

For uncomplicated urinary tract infections in women, a single oral dose of fosfomycin tromethamine 5.61 g (equivalent to 3 g of fosfomycin) dissolved in liquid is used. A longer treatment course is probably necessary for infections at other sites (eg, prostate [1]).

Dosing considerations reference

Drugs Mentioned In This Article

Drug Name Select Trade
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest


View All
Overview of Zika Virus Infection
Overview of Zika Virus Infection
3D Models
View All
3D Model